MetaBlok TM
MetaBlok is a new drug candidate and potential treatment for inflammation, sepsis and cancer metastasis.
Arch is currently pursuing clinical development of Metablok to prevent acute kidney injury caused by inflammation and expects...
MetaBlok™
Potential treatment for inflammation and cancer metastasis
AB569
Drug candidate for treating antibiotic resistant infections
AB569: Treatment for Drug Resistant Bacterial Infections
AB569 is a new drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and urinary tract. It also has potential to be modified for use in...
AB569 Principal Scientist
Lead scientist for AB569 which targets Respiratory Pseudomonas Infections
[yjsgimgs image="images/arch_content_images/headshots/drHasset.png" class="" title="" link="" target="" effect="none"]
Dr. Hassett
Dr. Hassett is a Professor in the Department of Molecular Genetics, Biochemistry and Microbiology...
Arch Biopartners to Seek Regulatory Guidance From the U.S FDA for AB569
TORONTO, June 19, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio-based biotechnology company, today announced that it...
BORG
Peptide Solid Surface Interface
Peptide Solid Surface Interface
Arch has developed a group of novel synthetic peptides and peptide conjugates that employ a novel chemistry (non-toxic, and environmentally friendly process) to react with solid surfaces such as metals, and plastics...
BORG Peptide Solid Surface Interface Scientists
Lead scientists for BORG Peptides
[yjsgimgs image="images/arch_content_images/headshots/rIrvin.png" class="" title="" link="" target="" effect="none"]
Randall Irvin
Randall Irvin is Professor of Medical Microbiology and Immunology at the University of Alberta. He previously was a faculty...
A peptide-based biological coating for enhanced corrosion resistance of titanium alloy biomaterials in chloride-containing fluids
Authors
Muruve N, Feng Y, Platnich J, Hassett...
MetaMX™
Targeting Brain Tumor Initiating Cells
Brain Tumor Initiating Cell Targeting
MetaMx™ is composed of novel, synthetic peptides that target and attach to BTICs and invasive glioma cells, for the purpose of imaging, diagnosis and developing targeted therapies to improve patient outcomes...
